Drug class effects: Definitions and practical applications;Efeitos de classe de medicamentos: Definição e aplicações práticas

Revista Portuguesa de Cardiologia

Volumn 21, Issue 9, 2002, Pages 1031-1042

  Soares, Isabel ^a   Vaz Carneiro, António ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Drug class effect; Evidence based cardiology; Iatrogenic complications; Levels of evidence

Indexed keywords

ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DRUG CLASSIFICATION; DRUG EFFECT; DRUG INDUSTRY; ENZYME INHIBITION; HUMAN; HYPERTENSION; IATROGENIC DISEASE; PRACTICE GUIDELINE; REVIEW;

EID: 0036748906     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. McAlister FA, Laupacis A, Wells GA, Sackett DL, for the Evidence-Based Medicine Working Group. Users' guides to the medical literature. XIX. Applying clinical trial results. B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999;282:1371-7.
2. Guyatt GH, Rennie D, editors. User's Guides to the Medical Literature. A Manual for Evidence-Based Clinical Practice. Chicago: JAMA & Archives Journals AMA 2001.
3. Carneiro AV. Níveis de evidência cientĩfica e graus de recomendação de esquemas de tratamento. Informação Terapêutica 2000;Jan-Mar:03-04.
4. Heidenreich PA, McDonald KM, Hastie T, Fadel B, Hagan V, Lee BK, Hlatky MA. Meta-analysis of trials comparing b-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999;281:1927-36.
5. Guyatt GH, Sackett DL, Cook DJ. The Evidence-Based Medicine Working Group. Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? JAMA 1994;271:59-63.
6. Evidence-Based Medicine. How to practice and teach EBM. Edinburgh: Churchill Livingstone 2000.
7. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995;273:1450-6.
8. Waldo AL, Camm AJ, deRuyter H, for the SWORD Investigators. Effect of d-sotalol on mortality in patients with severe left ventricular dysfunction after recent and remote myocardial infarction: survival with oral d-sotalol. Lancet 1996;348:7-12.
9. Greene WL, Concato J, Feinstein AR. Claims of equivalence in medical research: are they supported by the evidence? Ann Int Med 2000;132:715-22.
10. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary, disease. JAMA 1999;282:2340-6.
11. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998;97:1440-5.